Table 1. Patients’ characteristics.
| Characteristics | Value |
|---|---|
| Sex | |
| Male | 17 (73.9) |
| Female | 6 (26.1) |
| Age (years) | 73 [56–85] |
| KPS | |
| <90 | 14 (60.9) |
| ≥90 | 9 (39.1) |
| Previous lung resection | 2 (8.7) |
| Smoking history | |
| Former/current | 15 (65.2) |
| Never | 8 (34.8) |
| EGFR mutation | 2 (8.7) |
| ALK mutation | 2 (8.7) |
| Pathological diagnosis | |
| Squamous | 8 (34.8) |
| Adenocarcinoma | 15 (65.2) |
| Tumor location | |
| Right upper lobe | 9 (39.1) |
| Right middle lobe | 0 (0) |
| Right lower lobe | 5 (21.7) |
| Left upper lobe | 8 (34.8) |
| Left lower lobe | 1 (4.35) |
| T staging | |
| T1 | 17 (73.9) |
| T2 | 6 (26.1) |
| CCI | 5 [4–8] |
| Fraction of SBRT | 5–10 |
| BED of SBRT | 82.5–120 Gy |
Data are presented as n (%), range or median [range]. BED, biologically effective dose; CCI, Charlson Comorbidity Index; KPS, Karnofsky Performance Status; SBRT, stereotactic body radiotherapy; T, tumor.